GoodRx Holdings, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
GDRX$3.65+4.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year Ended December 31, | |||
|---|---|---|---|
| (in thousands, except per share amounts) | 2025 | 2024 | 2023 |
| Revenue | $796,853 | $792,324 | $750,265 |
| Costs and operating expenses: | |||
| Cost of revenue, exclusive of depreciation and amortization presented separately below | 57,597 | 48,215 | 66,925 |
| Product development and technology | 121,026 | 123,749 | 135,836 |
| Sales and marketing | 331,560 | 367,114 | 341,328 |
| General and administrative | 113,960 | 117,862 | 125,515 |
| Depreciation and amortization | 85,218 | 69,538 | 107,668 |
| Total costs and operating expenses | 709,361 | 726,478 | 777,272 |
| Operating income (loss) | 87,492 | 65,846 | (27,007) |
| Other expense, net: | |||
| Other income (expense) | 718 | (2,660) | (4,008) |
| Loss on extinguishment of debt | — | (2,077) | — |
| Interest income | 10,933 | 23,273 | 32,171 |
| Interest expense | (42,605) | (52,922) | (56,728) |
| Total other expense, net | (30,954) | (34,386) | (28,565) |
| Income (loss) before income taxes | 56,538 | 31,460 | (55,572) |
| Income tax (expense) benefit | (26,099) | (15,070) | 46,704 |
| Net income (loss) | $30,439 | $16,390 | $(8,868) |
| Earnings (loss) per share: | |||
| Basic | $0.09 | $0.04 | $(0.02) |
| Diluted | $0.09 | $0.04 | $(0.02) |
| Weighted average shares used in computing earnings (loss) per share: | |||
| Basic | 356,327 | 385,737 | 410,315 |
| Diluted | 356,973 | 392,172 | 410,315 |
| Stock-based compensation included in costs and operating expenses: | |||
| Cost of revenue | $357 | $320 | $610 |
| Product development and technology | 22,547 | 24,649 | 30,096 |
| Sales and marketing | 20,207 | 33,374 | 20,311 |
| General and administrative | 33,515 | 40,683 | 53,803 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.